Lynn A. Hyde

发表

fMRI study of olfactory processing in mice under three anesthesia protocols: Insight into the effect of ketamine on olfactory processing

Fuqiang Zhao, Xiangjun Meng, Andrea K. Houghton, 2020, NeuroImage.

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Michael Tanen, Matthew E. Kennedy, Wei Li, 2016, Science Translational Medicine.

Pharmacological BACE Inhibition Improves Axonal Regeneration in Nerve Injury and Disease Models

Lynn A. Hyde, M. Kennedy, L. Hyde, 2020, Neurotherapeutics.

In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

Lynn A. Hyde, G. Higgins, J. Clader, 2013, International journal of Alzheimer's disease.

Studies to Investigate the in Vivo Therapeutic Window of the γ-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide (LY411,575) in the CRND8 Mouse

Lynn A. Hyde, G. Higgins, J. Clader, 2006, Journal of Pharmacology and Experimental Therapeutics.

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

Lynn A. Hyde, N. Hastings, B. Butts, 2017, Molecular Neurodegeneration.

BACE1 – but not BACE2 – function is critical for metabolic disorders induced by high-fat diets in C57BL/6N mice

Lynn A. Hyde, T. Sorg, J. Cumming, 2021, bioRxiv.

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.

Qin Jiang, William J Greenlee, Xia Chen, 2016, Journal of medicinal chemistry.

The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent species.

Lynn A. Hyde, D. Tulshian, R. Hodgson, 2011, European journal of pharmacology.

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Lynn A. Hyde, Z. Yin, M. Kennedy, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.

Lynn A. Hyde, W. Greenlee, A. Stamford, 2012, Bioorganic & medicinal chemistry letters.

Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation.

William Greenlee, Lynn Hyde, Xia Chen, 2012, Journal of medicinal chemistry.

Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage

Lynn A. Hyde, D. Holder, M. Kennedy, 2017, Journal of Alzheimer's disease : JAD.

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates.

Lynn A. Hyde, W. Greenlee, A. Stamford, 2016, Journal of medicinal chemistry.

Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction.

Suresh Babu, William J Greenlee, Xia Chen, 2012, ACS medicinal chemistry letters.

Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability.

Lynn A. Hyde, W. Greenlee, J. Clader, 2009, Bioorganic & medicinal chemistry letters.

MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

Lynn A. Hyde, E. Hostetler, J. Uslaner, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology

Lynn A. Hyde, J. Melchor, J. Hess, 2015, Molecular Neurodegeneration.

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.

Marc Poirier, Michael W. Miller, Christian Mirescu, 2017, Journal of medicinal chemistry.

Discovery of a Tetrahydrobenzisoxazole Series of γ-Secretase Modulators.

Lynn A. Hyde, W. Greenlee, A. Palani, 2017, ACS medicinal chemistry letters.

Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.

Lynn A. Hyde, R. Xu, J. Clader, 2015, Journal of medicinal chemistry.

Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo.

Lynn A. Hyde, W. Greenlee, Xiaohong Zhu, 2012, Journal of medicinal chemistry.

Generation of Leads for γ-Secretase Modulation.

Lynn A. Hyde, A. Palani, Zhaoning Zhu, 2020, Journal of medicinal chemistry.

The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.

Lynn A. Hyde, W. Greenlee, Wei Zhou, 2013, Bioorganic & medicinal chemistry letters.

Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators.

Lynn A. Hyde, W. Greenlee, Wei Zhou, 2011, ACS medicinal chemistry letters.

Discovery of fused 5,6-bicyclic heterocycles as γ-secretase modulators.

Lynn A. Hyde, W. Greenlee, A. Palani, 2011, Bioorganic & medicinal chemistry letters.

Iminoheterocycles as gamma-secretase modulators.

Lynn A. Hyde, J. Voigt, Zhaoning Zhu, 2010, Bioorganic & medicinal chemistry letters.

The Discovery of Pyridone and Pyridazone Heterocycles as γ-Secretase Modulators.

Lynn A. Hyde, W. Greenlee, Xiaohong Zhu, 2010, ACS medicinal chemistry letters.

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

Lynn A. Hyde, J. Uslaner, Sean M. Smith, 2011, Neuropharmacology.

Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination

Lynn A. Hyde, R. Hodgson, L. Hyde, 2011, Pharmacology Biochemistry and Behavior.

Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.

Lynn A. Hyde, W. Greenlee, Mark D. McBriar, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease.

Lynn A. Hyde, W. Greenlee, Wei Zhou, 2012, ACS medicinal chemistry letters.

SAR of tricyclic sulfones as γ-secretase inhibitors

Lynn A. Hyde, W. Greenlee, Mark D. McBriar, 2011 .

Tricyclic sulfones as orally active gamma-secretase inhibitors: synthesis and structure-activity relationship studies.

Lynn A. Hyde, W. Greenlee, R. Xu, 2010, Bioorganic & medicinal chemistry letters.

Tetracyclic sulfones as potent gamma-secretase inhibitors: synthesis and structure-activity relationship studies.

Lynn A. Hyde, W. Greenlee, R. Xu, 2010, Bioorganic & medicinal chemistry letters.

MitoPark mice, an animal model of Parkinson’s disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A2A antagonist SCH 412348

Lynn A. Hyde, S. Grauer, R. Hodgson, 2014, Psychopharmacology.

Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors.

Lynn A. Hyde, W. Greenlee, Mark D. McBriar, 2013, Bioorganic & medicinal chemistry letters.

Pharmacological BACE Inhibition Improves Axonal Regeneration in Nerve Injury and Disease Models

Lynn A. Hyde, M. Kennedy, L. Hyde, 2020, Neurotherapeutics.

Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.

Lynn A. Hyde, A. Stamford, J. Cumming, 2018, Journal of medicinal chemistry.

Synthesis and SAR study of tricyclic sulfones as γ-secretase inhibitors: C-6 and C-8 positions.

Lynn A. Hyde, W. Greenlee, R. Xu, 2011, Bioorganic & medicinal chemistry letters.

Lynn A. Hyde, D. Tulshian, R. Hodgson, 2011, European journal of pharmacology.

Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology

Lynn A. Hyde, J. Melchor, J. Hess, 2015, Molecular Neurodegeneration.